PA
APGE

Parallel Advisors’s Apogee Therapeutics APGE Stock Holding History

Parallel Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.3K Buy
296
+237
+402% +$21.4K ﹤0.01% 2294
2026
Q1 		$4.97K Buy
+59
New +$4.29K ﹤0.01% 3032
2025
Q1 		– Sell
-6
Closed -$272 – 3514
2024
Q4 		$272 Sell
6
-5
-45% -$255 ﹤0.01% 3331
2024
Q3 		$646 Buy
+11
New +$527 ﹤0.01% 3134

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Parallel Advisors's APGE Position: Q2 2026 in Review

Parallel Advisors increased its Apogee Therapeutics (APGE) stake by 402% in Q2 2026, buying an estimated $21.4K and bringing the position to 296 shares worth $39.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2294.

Parallel Advisors first reported a position in APGE in Q3 2024 and has held it in 4 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Parallel Advisors held 296 shares of Apogee Therapeutics worth $39.3K as of Q2 2026.
  • Parallel Advisors bought 237 Apogee Therapeutics shares in Q2 2026, an estimated $21.4K.
  • Apogee Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2294 holding.
  • Parallel Advisors first reported a position in Apogee Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.